Cat. No.: HY-100573

Necrosulfonamide

140 Cited Publications

Customer Review

Based on 140 publication(s) in Google Scholar

Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.

For research use only. We do not sell to patients.

Purity: 98.61%
CAS No.: 1360614-48-7
Formula: C₁₈H₁₅N₅O₆S₂
Molecular Weight:461.47

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Necrosulfonamide Chemical Structure

CAS No.: 1360614-48-7

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (140)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[3]^[6]

NLRP3

Caspase-1

IL-6

IL-1β

iNOS

HO-1

All Caspase Isoforms :

All NOD-like Receptor (NLR) Isoforms :

All TNF Receptor Isoforms :

All Interleukin Related Isoforms :

All NO Synthase Isoforms :

All Heme Oxygenase (HO) Isoforms :

HO-1
HO-2

Cellular Effect

Cell Line	Type	Value	Description	References
HT-29	IC₅₀	<200 nM Compound: 66; NSA	Anti-neprotic activity in human HT-29 cells assessed as reduction in TSZ-induced necroptosis incubated for 24 hrs by cell titer glo-based luminescence assay Anti-neprotic activity in human HT-29 cells assessed as reduction in TSZ-induced necroptosis incubated for 24 hrs by cell titer glo-based luminescence assay	[PMID: 31622096]
HT-29	IC₅₀	<1 μM Compound: 34; NSA	Anti-necroptotic activity in human HT-29 cells assessed as inhibition of T/S/Z induced necroptosis by CellTiter-Glo Luminescent Cell Viability assay Anti-necroptotic activity in human HT-29 cells assessed as inhibition of T/S/Z induced necroptosis by CellTiter-Glo Luminescent Cell Viability assay	[PMID: 36781172]
HT-29	IC₅₀	124 nM Compound: 34; NSA	Anti-necroptotic activity in human HT-29 cells assessed as inhibition of T/S/Z induced necroptosis by CellTiter-Glo Luminescent Cell Viability assay Anti-necroptotic activity in human HT-29 cells assessed as inhibition of T/S/Z induced necroptosis by CellTiter-Glo Luminescent Cell Viability assay	[PMID: 36781172]
HT-29	EC₅₀	447 nM Compound: NSA; A1	Anti-necroptosis activity against TNFalpha/Smac mimetic/Z-VAD-fmk-induced human HT-29 cells measured after 24 hrs by CellTiter-Glo assay Anti-necroptosis activity against TNFalpha/Smac mimetic/Z-VAD-fmk-induced human HT-29 cells measured after 24 hrs by CellTiter-Glo assay	[PMID: 38442525]
Jurkat	IC₅₀	<1 μM Compound: 34; NSA	Anti-necroptotic activity in FADD null human Jurkat cells assessed as inhibition of T/S/Z induced necroptosis by CellTiter-Glo Luminescent Cell Viability assay Anti-necroptotic activity in FADD null human Jurkat cells assessed as inhibition of T/S/Z induced necroptosis by CellTiter-Glo Luminescent Cell Viability assay	[PMID: 36781172]

In Vitro

Necrosulfonamide (0-10 μM) blocks necrosis in both human colon cancer HT-29 cells and FADD null human T cell leukemia Jurkat cells with IC₅₀s both less than 1 μM, but it has no effect on mouse cells, for that the cysteine at the 86th position in human MLK1 is replaced by tryptophan in the mouse MLKL after covalent modification^[1].
Necrosulfonamide (6 h) acts downstream of RIP3 activation, it does not inhibit the interaction or phosphorylation between RIP1 and RIP3; but enhances these processes in RIP3-HT-29 cells^[1].
Necrosulfonamide (10 μM, 45 min-25 h) inhibits the release of inflammatory factors and pyroptosis in BMDMs and NCM460 cells necroptosis and has no effect on the vitality of the two types of cells^[4].
Necrosulfonamide (0.1-100 μM) protects primary cultured astrocytes and human astrocytes against oxygen-glucose deprivation and reoxygenation (OGD/Re)-induced cell injury, reduces the number of PI-positive cells and inhibits the levels of necroptosis-related proteins^[5].
Necrosulfonamide (0.1-1 μM, 6 h) reverses pyroptosis-induced inhibition of proliferation and differentiation of osteoblasts through the NLRP3/caspase-1/GSDMD pathway in hFOB 1.19 cells^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA Assay^[4]

Cell Line:

BMDMs
Concentration:

10 μM
Incubation Time:

1 h, followed by LPS for 6 h
Result:

Inhibited the massive release of IL-1β and TNF-α.

Apoptosis Analysis^[6]

Cell Line:

hFOB 1.19 cells
Concentration:

0.1, 0.5, 1 μM
Incubation Time:

6 h
Result:

Significantly decreased the pyroptosis rate at 0.5 μM and 1.0 μM.
Did not significantly change the viability or pyroptosis rate of osteoblasts alone.

RT-PCR^[6]

Cell Line:

hFOB 1.19 cells
Concentration:

0.1, 0.5, 1 μM
Incubation Time:

6 h
Result:

Significantly decreased the pyroptosis rate at 0.5 μM and 1.0 μM.
Did not significantly change the viability or pyroptosis rate of osteoblasts alone.

Western Blot Analysis^[6]

Cell Line:

hFOB 1.19 cells
Concentration:

0.1, 0.5, 1 μM
Incubation Time:

6 h
Result:

Inhibited the activation of the pyroptosis execution proteins (caspase-1, GSDMD).
Increased the protein expressions of key osteogenic markers (ALP, Runx2, COL-1, OPN, BMP-2)

ELISA Assay^[6]

Cell Line:

hFOB 1.19 cells
Concentration:

0.1, 0.5, 1 μM
Incubation Time:

6 h
Result:

Reduced the levels of IL-6, TNF-α and IL-1β in the cell supernatant

In Vivo

Necrosulfonamide (20 mg/kg, i.p., single dose) alleviates Lipopolysaccharide (HY-D1056A1)/D-galactosamine (HY-42682)-induced acute liver failure in mice^[2].
Necrosulfonamide (1-5 mg/kg, i.p., once daily for 3 days) reduces oxidative Stress, inflammation, and dopaminergic neuronal cell death in MPTP (HY-15608)-induced Parkinson’s disease mouse model^[3].
Necrosulfonamide (20-40 mg/kg, i.p., once other daily for 5-7 days) ameliorates Inflammatory bowel disease (IBD) in mice via inhibiting GSDMD-medicated pyroptosis and MLKL-mediated necroptosis^[4].
Necrosulfonamide (40-80 nmol, intracerebroventricular administration, single dose) produces neuroprotective effects against ischemia/reperfusion (I/R)-induced acute brain injury in rats^[5].
Necrosulfonamide promotes hair growth and prevents hair follicle degeneration in androgenetic alopecia (AGA) mice through Wnt signaling^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

LPS/D-galactosamine-induced acute liver failure established in male 8-week-old specific pathogen-free (SPF) grade C57BL/6J mice^[2]
Dosage:

20 mg/kg
Administration:

Intraperitoneal injection (i.p.), single dose before the model creation process
Result:

Increased the survival rate of mice, reduced the serum ALT level, and alleviated liver tissue damage.
Reduced the levels of serum IL-1β and IL-18.
Downregulated the protein levels of NLRP3, cleaved caspase-1, cleaved caspase-11, and mature IL-1β.

Animal Model:

MPTP-induced Parkinson’s disease mouse model established in male C57BL/6 mice (24-25 g, 9-10 weeks old)^[3]
Dosage:

1 and 5 mg/kg
Administration:

Intraperitoneal injection (i.p.), single dose before the model creation process
Result:

Reduced the death of dopaminergic neurons and restores neurotrophic factors.
Reduced the levels of pro-inflammatory mediators such as iNOS, TNF-α, IL-1β, and IL-6.
Reduced the activation of microglial cells and astrocytes in the substantia nigra and striatum.
Restored the expression of the core antioxidant transcription factor Nrf2 and a series of downstream antioxidant enzymes (HO-1, catalase, MnSOD, GCLC, GCLM).
Effectively inhibited the expression of p-MLKL and MLKL, and reduced the number of p-MLKL⁺/TH⁺ and p-MLKL⁺/OX-42⁺ cells.

Animal Model:

DSS (HY-116282C) induced IBD model established in male 6- to 9-week-old C57BL/6 mice weighting 22-26 g ^[4]
Dosage:

20 and 40 mg/kg (prevent) and 20 mg/kg (treatment)
Administration:

Intraperitoneal injection (i.p.), once every other day for 7 days (prevent) and for 5 days (treatment)
Result:

Significantly reduced the DAI score and increased the colon length in a dose-dependent manner.
Reduced the levels of serum TNF-α and MPO.
Reduced the inflammatory score, retained more goblet cells and mucus layers, and decreased the infiltration of CD4⁺ T cells, CD8⁺ T cells and macrophages (F4/80⁺) in the colon tissue.
Reduced the levels of 16sRNA, IL-1β, TNF-α, and IL-6 mRNA, inhibited p-p65, and promoted Nrf2 expression.
Reduced the death of colonic epithelial cells and p-MLKL-positive cells, and inhibited the expression of necroptosis markers (p-MLKL, p-RIPK1, p-RIPK3) and pyroptosis markers (N-GSDMD).

Animal Model:

Transient middle cerebral artery occlusion model established in adult male SD rats (290-310 g)^[5]
Dosage:

40 and 80 nmol
Administration:

Intracerebroventricular administration, single dose
Result:

Significantly reduced the volume of cerebral infarction.
Significantly improved the neurological function score and the asymmetry of forelimb usage.
Significantly reduced the number of PI-positive cells.
Inhibited the total expression levels of MLKL/p-MLKL, RIP3K/p-RIP3K, and RIP1K/p-RIP1K in the ischemic penumbra tissue, and translocation of MLKL/p-MLKL and RIP3K/p-RIP3K to the nucleus and nuclear membrane.

Chemical Information

CAS No. 1360614-48-7
Appearance Solid
Molecular Weight 461.47
Formula C₁₈H₁₅N₅O₆S₂
Color Light yellow to yellow
SMILES

O=C(NC1=CC=C(S(=O)(NC2=NC=CN=C2OC)=O)C=C1)/C=C/C3=CC=C([N+]([O-])=O)S3
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (140)

All Cell Proliferation/Viability AssayIn Vivo Efficacy StudyIHCWB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Disruption of heme homeostasis by nuclear receptor Nur77 induces pyroptosis through granzyme B-dependent GSDMC cleavage. [Abstract]

2025 Dec 17;10(1):413. PMID: 41407678
Circulation

Cannabinoid Receptor 2-Centric Molecular Feedback Loop Drives Necroptosis in Diabetic Heart Injuries. [Abstract]

2023 Jan 10;147(2):158-174. PMID: 36448459
Nat Immunol

Delaying pyroptosis with an AI-screened gasdermin D pore blocker mitigates inflammatory response. [Abstract]

2025 Oct;26(10):1660-1672. PMID: 40954252

Necrosulfonamide purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Oct;26(10):1660-1672. [Abstract]

Wild-type (WT) and Gsdmd^−/− mice were intraperitoneally injected with 15 mg/kg (body weight) LPS and treated with normal saline, SK56 (1 mg/kg (body weight) i.v.) or 50 mg/kg (body weight) DSF, 50 mg/kg (body weight) DMF or 20 mg/kg (body weight) Necrosulfonamide (NSA) i.p. at 16 h after LPS injection. Blood AST, BUN, ALT and CK levels in wild-type and Gsdmd^−/− mice treated as in a at day 2 after LPS injection; n = 6 mice.
Adv Mater

Impairing Tumor Metabolic Plasticity via a Stable Metal-Phenolic-Based Polymeric Nanomedicine to Suppress Colorectal Cancer. [Abstract]

2023 Jun;35(23):e2300548. PMID: 36917817

Necrosulfonamide purchased from MedChemExpress. Usage Cited in: Adv Mater. 2023 Jun;35(23):e2300548. [Abstract]

Necrosulfonamide (1 μM; 4 h) pretreatment of CT26 cells reduces the cytotoxicity induced by Mal-DOX, NP, and pOEG-b-nSH@NP, but has no effect on that induced by doxorubicin (DOX).
Cell Res

HSPA8 acts as an amyloidase to suppress necroptosis by inhibiting and reversing functional amyloid formation. [Abstract]

2023 Nov;33(11):851-866. PMID: 37580406
Mater Today

2026 Jan 7;92:453-472.
Nat Aging

Converting cell death into senescence by PARP1 inhibition improves recovery from acute oxidative injury. [Abstract]

2024 May 9. PMID: 38724734
Nat Cell Biol

Full-length GSDME mediates pyroptosis independent from cleavage. [Abstract]

2024 Sep;26(9):1545-1557. PMID: 38997456
Nat Cell Biol

De novo pyrimidine biosynthetic complexes support cancer cell proliferation and ferroptosis defence. [Abstract]

2023 Jun;25(6):836-847. PMID: 37291265
Nat Commun

RIPK1 kinase drove brain microvascular endothelial cells death and blood-brain barrier disruption in neonatal Escherichia coli meningitis. [Abstract]

2025 Aug 7;16(1):7309. PMID: 40774959

Necrosulfonamide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 7;16(1):7309. [Abstract]

hBMECs were pretreated with Necrosulfonamide (NSA) (20 μM) or zVAD alone or in combination for 0.5 h, followed by infection with RS218 at an MOI of 1 or 10. LDH release (n=6 biologically independent samples) was assayed.
Nat Commun

Injectable ECM-mimetic dynamic hydrogels abolish ferroptosis-induced post-discectomy herniation through delivering nucleus pulposus progenitor cell-derived exosomes. [Abstract]

2025 Apr 1;16(1):3131. PMID: 40169595
Nat Commun

Identification of purine biosynthesis as an NADH-sensing pathway to mediate energy stress. [Abstract]

2022 Nov 17;13(1):7031. PMID: 36396642
Cell Death Differ

Epithelial MST1 deficiency promotes pyroptosis and aggravates inflammatory bowel disease via the YAP/p73 signaling pathway. [Abstract]

2025 Sep 26. PMID: 41006633

Necrosulfonamide purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2025 Sep 26. [Abstract]

Necrosulfonamide (NSA) (20 mg/kg; i.p., every other day) significantly alleviates histological damage in the colonic tissue of MST1^Vil-KO mice.

Necrosulfonamide purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2025 Sep 26. [Abstract]

Necrosulfonamide (NSA) (20 mg/kg; i.p., every other day) significantly reduces the expression levels of IL-1β and IL-18 in MST1^Vil-KO mice.
Cell Death Differ

Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cells. [Abstract]

2021 Apr;28(4):1222-1236. PMID: 33097833
Autophagy

CAMK2/CaMKII activates MLKL in short-term starvation to facilitate autophagic flux. [Abstract]

2022 Apr;18(4):726-744. PMID: 34282994
Adv Sci (Weinh)

Novel Swelling-Lytic Cell Death Triggered by Cargo-Free Ionizable Lipid Nanoparticles. [Abstract]

2025 Aug 7:e09208. PMID: 40776529
Adv Sci (Weinh)

PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma. [Abstract]

2025 May 23:e04372. PMID: 40405713
Adv Sci (Weinh)

Donafenib and GSK-J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression. [Abstract]

2023 Aug;10(22):e2206798. PMID: 37330650
J Clin Invest

Gasdermin D inhibition confers antineutrophil-mediated cardioprotection in acute myocardial infarction. [Abstract]

2022 Jan 4;132(1):e151268. PMID: 34752417
Theranostics

Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK. [Abstract]

2020 Jun 19;10(17):7710-7729. PMID: 32685015
J Adv Res

Hypericin photoactivation induces triple-negative breast cancer cells pyroptosis by targeting the ROS/CALR/Caspase-3/GSDME pathway. [Abstract]

2025 Jan 25:S2090-1232(25)00059-1. PMID: 39870303
J Exp Clin Cancer Res

TCF3 activates super-enhancer-driven TRIB2 overexpression to suppress ferroptosis and promote hepatoblastoma proliferation. [Abstract]

2025 Dec 29;44(1):329. PMID: 41462308
J Exp Clin Cancer Res

Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer. [Abstract]

2021 Jun 23;40(1):206. PMID: 34162423
Cell Discov

Bergeyella cardium variant induces a unique cytoplasmic vacuolization cell death floatptosis in macrophage. [Abstract]

2025 Oct 21;11(1):83. PMID: 41115953
Cell Discov

Ferroptosis-induced SUMO2 lactylation counteracts ferroptosis by enhancing ACSL4 degradation in lung adenocarcinoma. [Abstract]

2025 Oct 7;11(1):81. PMID: 41057295
Redox Biol

Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation. [Abstract]

2021 May:41:101942. PMID: 33770521
EBioMedicine

Analysis of multiple programmed cell death-related prognostic genes and functional validations of necroptosis-associated genes in oesophageal squamous cell carcinoma. [Abstract]

2024 Jan:99:104920. PMID: 38101299
EBioMedicine

Single cell RNA-seq analysis identifies ferroptotic chondrocyte cluster and reveals TRPV1 as an anti-ferroptotic target in osteoarthritis. [Abstract]

2022 Oct;84:104258. PMID: 36137413
MedComm (2020)

Noncanonical feedback loop between "RIP3-MLKL" and "4EBP1-eIF4E" promotes neuronal necroptosis. [Abstract]

2025 Feb 18;6(3):e70107. PMID: 39974664
Cell Rep Med

5-HT reuptake blockade induces pyroptosis in BRAFV600E-mutated melanomas via remodeling histone serotonylation. [Abstract]

2026 Jan 20;7(1):102537. PMID: 41494533
Pharmacol Res

GSTA1/CTNNB1 axis facilitates sorafenib resistance via suppressing ferroptosis in hepatocellular carcinoma. [Abstract]

2024 Nov 5:210:107490. PMID: 39510148
Cancer Lett

SIK1 promotes ferroptosis resistance in pancreatic cancer via HDAC5-STAT6-SLC7A11 axis. [Abstract]

2025 Apr 16:217726. PMID: 40250791
Cancer Lett

A novel protein encoded by circFOXP1 enhances ferroptosis and inhibits tumor recurrence in intrahepatic cholangiocarcinoma. [Abstract]

2024 Jun 28:217092. PMID: 38945202
J Neuroinflammation

GSDMD/Drp1 signaling pathway mediates hippocampal synaptic damage and neural oscillation abnormalities in a mouse model of sepsis-associated encephalopathy. [Abstract]

2024 Apr 16;21(1):96. PMID: 38627764
Int J Biol Sci

O-GlcNAcylation of ZEB1 facilitated mesenchymal pancreatic cancer cell ferroptosis. [Abstract]

2022 Jun 21;18(10):4135-4150. PMID: 35844792
Cell Death Dis

Necroptosis of macrophage is a key pathological feature in biliary atresia via GDCA/S1PR2/ZBP1/p-MLKL axis. [Abstract]

2023 Mar 1;14(3):175. PMID: 36859525
Cell Death Dis

SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase. [Abstract]

2023 Jan 12;14(1):22. PMID: 36635256
Cell Death Dis

GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis. [Abstract]

2021 Apr 30;12(5):426. PMID: 33931597
Cell Death Dis

"Iron free" zinc oxide nanoparticles with ion-leaking properties disrupt intracellular ROS and iron homeostasis to induce ferroptosis. [Abstract]

2020 Mar 13;11(3):183. PMID: 32170066
Sci China Life Sci

Melatonin decreases GSDME mediated mesothelial cell pyroptosis and prevents peritoneal fibrosis and ultrafiltration failure. [Abstract]

2024 Feb;67(2):360-378. PMID: 37815699
Stroke

Coupling Between Interleukin-1R1 and Necrosome Complex Involves in Hemin-Induced Neuronal Necroptosis After Intracranial Hemorrhage. [Abstract]

2018 Oct;49(10):2473-2482. PMID: 30355103
Dev Cell

Lactylation of LSD1 is an acquired epigenetic vulnerability of BRAFi/MEKi-resistant melanoma. [Abstract]

2025 Mar 20:S1534-5807(25)00121-2. PMID: 40132584
Int J Biol Macromol

Light-crosslinked gelatin methacrylate hydrogel prevents intervertebral disc degeneration by delivering 10-hydroxy-2-decenoic acid to inhibit ferroptosis via NF-κB signaling. [Abstract]

2025 Oct 21;331(Pt 2):148454. PMID: 41130468
Phytomedicine

Nuciferine ameliorates steroid-induced osteonecrosis of the femoral head by inhibiting BMSCs ferroptosis via HIF-1α. [Abstract]

2026 Jun:155:158070. PMID: 41861683
Phytomedicine

Baohuoside I induces GSDME-dependent pyroptosis and synergistically inhibits lung adenocarcinoma with cisplatin. [Abstract]

2026 Apr:153:157899. PMID: 41643445
Phytomedicine

Andrographolide induces ferroptosis in colorectal cancer via P53-mediated downregulation of the SLC7A11/GPX4 signaling pathway. [Abstract]

2025 Nov 25:148:157470. PMID: 41187650
Phytomedicine

Anti-inflammatory effect of Danhong injection through inhibition of GSDMD-mediated pyroptosis. [Abstract]

2023 May:113:154743. PMID: 36893672
Free Radic Biol Med

Targeting PDK4 to mitigate osimertinib-induced cardiotoxicity: Insights into mitochondria-endoplasmic reticulum crosstalk and necroptosis. [Abstract]

2025 Aug 9:240:267-283. PMID: 40789497
Free Radic Biol Med

Resveratrol induces ferroptosis in triple-negative breast cancer through NEDD4L-mediated GPX4 ubiquitination and degradation. [Abstract]

2025 Aug 1:235:231-247. PMID: 40316059
Free Radic Biol Med

Crucial roles of asprosin in cisplatin-induced ferroptosis and acute kidney injury. [Abstract]

2024 Dec 9:227:296-311. PMID: 39653130
Free Radic Biol Med

Targeting ALDH2 to augment platinum-based chemosensitivity through ferroptosis in lung adenocarcinoma. [Abstract]

2024 Aug 29:S0891-5849(24)00620-8. PMID: 39216560
NPJ Precis Oncol

Integrating bulk, single-cell, and spatial transcriptomics to identify and functionally validate novel targets to enhance immunotherapy in NSCLC. [Abstract]

2025 Apr 16;9(1):112. PMID: 40240582
Biomed Pharmacother

Elesclomol-copper synergizes with imidazole ketone erastin by promoting cuproptosis and ferroptosis in myelodysplastic syndromes. [Abstract]

2024 May 10:175:116727. PMID: 38733771
J Transl Med

CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis. [Abstract]

2022 Oct 2;20(1):444. PMID: 36184616
PLoS Biol

RIPK1 is required for ZBP1-driven necroptosis in human cells. [Abstract]

2025 Feb 21;23(2):e3002845. PMID: 39982916
Cell Death Discov

SLC25A10 promotes cisplatin resistance by inhibiting ferroptosis in cervical cancer. [Abstract]

2025 Oct 7;11(1):447. PMID: 41057306
Cell Death Discov

RIPK1 S213E mutant suppresses RIPK1-dependent cell death by preventing interactions with RIPK3 and CASP8. [Abstract]

2025 Jul 25;11(1):345. PMID: 40715038
Cell Death Discov

HDAC11 promotes both NLRP3/caspase-1/GSDMD and caspase-3/GSDME pathways causing pyroptosis via ERG in vascular endothelial cells. [Abstract]

2022 Mar 12;8(1):112. PMID: 35279683
Cell Death Discov

Salmonella pSLT-encoded effector SpvB promotes RIPK3-dependent necroptosis in intestinal epithelial cells. [Abstract]

2022 Feb 2;8(1):44. PMID: 35110556
Cell Rep

Autoinhibitory control of MLKL governs pseudokinase domain phosphorylation and oligomerization during necroptosis. [Abstract]

2026 Mar 20;45(4):117130. PMID: 41863805
Cell Rep

Pathogenic phosphorylation of linear ubiquitin machinery causes inflammasome sensor degradation. [Abstract]

2025 Sep 12;44(9):116286. PMID: 40944911
Clin Transl Med

Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation. [Abstract]

2023 Jun;13(6):e1300. PMID: 37337470
Cell Mol Life Sci

S100A8/A9-activated IFNγ+ NK cells trigger β-cell necroptosis in hepatitis B virus-associated liver cirrhosis. [Abstract]

2024 Aug 12;81(1):345. PMID: 39133305
J Agric Food Chem

Nobiletin Triggers Reactive Oxygen Species-Mediated Pyroptosis through Regulating Autophagy in Ovarian Cancer Cells. [Abstract]

2020 Feb 5;68(5):1326-1336. PMID: 31955565
J Agric Food Chem

Inorganic Selenium Induces Nonapoptotic Programmed Cell Death in PC-3 Prostate Cancer Cells Associated with Inhibition of Glycolysis. [Abstract]

2019 Sep 25;67(38):10637-10645. PMID: 31513389
J Invest Dermatol

CAMKK2 Defines Ferroptosis Sensitivity of Melanoma Cells by Regulating AMPK‒NRF2 Pathway. [Abstract]

2022 Jan;142(1):189-200.e8. PMID: 34242660
Biochem Pharmacol

STING activation in macrophages by vanillic acid exhibits antineoplastic potential. [Abstract]

2023 Jul:213:115618. PMID: 37211172
Biochem Pharmacol

ALOX5 Promotes Autophagy-dependent Ferroptosis by Activating the AMPK/mTOR Pathway in Melanoma. [Abstract]

2023 Jun:212:115554. PMID: 37080437
Chem Biol Interact

A novel non-nad-based PARP1 inhibitor, Japoflavone B, triggered Caspase-3/GSDME-mediated pyroptosis through ROS/p38/p53 pathway in NSCLC. [Abstract]

2025 Oct 22:420:111693. PMID: 40754060
J Ethnopharmacol

Yunnan baiyao exerts anti-glioma activity by inducing autophagy-dependent necroptosis. [Abstract]

2024 Aug 3:118658. PMID: 39103023
Mol Ther Oncol

Preclinical study of microphthalmia-associated transcription factor inhibitor ML329 in gastrointestinal stromal tumor growth. [Abstract]

2025 Apr 14;33(2):200983. PMID: 40343114
Cells

Targeting Wnt/β-Catenin Signaling Exacerbates Ferroptosis and Increases the Efficacy of Melanoma Immunotherapy via the Regulation of MITF. [Abstract]

2022 Nov 12;11(22):3580. PMID: 36429010
Drug Des Devel Ther

Role of GRP78 inhibiting artesunate-induced ferroptosis in KRAS mutant pancreatic cancer cells. [Abstract]

2019 Jul 2;13:2135-2144. PMID: 31456633
Int J Mol Sci

MED12 Dictates Epithelial Ovarian Cancer Cell Ferroptosis Sensitivity via YAP-TEAD1 Signaling. [Abstract]

2026 Jan 20;27(2):1020. PMID: 41596664
Int J Mol Sci

Caspase-8 Regulates Endoplasmic Reticulum Stress-Induced Necroptosis Independent of the Apoptosis Pathway in Auditory Cells. [Abstract]

2019 Nov 24;20(23):5896. PMID: 31771290
Biomolecules

Gasdermin D Inhibitor Necrosulfonamide Alleviates Angiotensin II-Induced Abdominal Aortic Aneurysms in Apolipoprotein E-Deficient Mice. [Abstract]

2024 Jun 19;14(6):726. PMID: 38927129
Front Cell Infect Microbiol

Dysregulation of Cytosolic c-di-GMP in Edwardsiella piscicida Promotes Cellular Non-Canonical Ferroptosis. [Abstract]

2022 Feb 4;12:825824. PMID: 35186798
Front Pharmacol

Polyphyllin Ⅲ-Induced Ferroptosis in MDA-MB-231 Triple-Negative Breast Cancer Cells can Be Protected Against by KLF4-Mediated Upregulation of xCT. [Abstract]

2021 May 10:12:670224. PMID: 34040532
Front Pharmacol

PINK1/Parkin-Mediated Mitophagy Regulation by Reactive Oxygen Species Alleviates Rocaglamide A-Induced Apoptosis in Pancreatic Cancer Cells. [Abstract]

2019 Sep 3:10:968. PMID: 31551778
mBio

A20 restricted PDCoV release through negative regulation of PANoptosis. [Abstract]

2026 Apr 8;17(4):e0008126. PMID: 41773863
Int Immunopharmacol

Colistin-induced acute kidney injury via zinc Dyshomeostasis-triggered GSDMD-executed Pyroptosis. [Abstract]

2026 Jan 1;168(Pt 1):115768. PMID: 41176907
Cancer Sci

PSMD14/E2F1 Axis-Mediated CENPF Promotes the Metastasis of Triple-Negative Breast Cancer Through Inhibiting Ferroptosis. [Abstract]

2025 Aug;116(8):2281-2295. PMID: 40365861
Transl Stroke Res

The Key Regulator of Necroptosis, RIP1 Kinase, Contributes to the Formation of Astrogliosis and Glial Scar in Ischemic Stroke. [Abstract]

2021 Dec;12(6):991-1017. PMID: 33629276

Necrosulfonamide purchased from MedChemExpress. Usage Cited in: Transl Stroke Res. 2021 Dec;12(6):991-1017. [Abstract]

Delayed administration of Necrosulfonamide (NSA) reduces the protein level of RIP3K or MLKL and GFAP after OGD/Re injury. Astrocytes are exposed to OGD for 6 h followed by reoxygenation for 24 h. NSA (1 μM) is added to the cells upon reoxygenation.
FASEB J

EM2, a Novel Elephantopus mollis H.B.K. Monomer, Enhances Radiosensitivity in Cervical Cancer Through Dual Inhibition of AKT and Autophagy. [Abstract]

2026 Jan 31;40(2):e71454. PMID: 41527777
Biochim Biophys Acta Mol Basis Dis

Oncogenic HNF4α inhibits ferroptotic cell death through activating SLC7A11 by recruiting p300/CBP in breast cancer. [Abstract]

2025 Aug;1871(6):167884. PMID: 40320185
FASEB J

Renal tubular epithelial cell necroptosis promotes tubulointerstitial fibrosis in patients with chronic kidney disease. [Abstract]

2022 Dec;36(12):e22625. PMID: 36331546
FASEB J

Serpina3c deficiency induced necroptosis promotes non-alcoholic fatty liver disease through β-catenin/Foxo1/TLR4 signaling. [Abstract]

2022 May;36(5):e22316. PMID: 35429042
J Inflamm Res

Calcitriol Alleviates Hyperosmotic Stress-Induced Corneal Epithelial Cell Damage via Inhibiting the NLRP3-ASC-Caspase-1-GSDMD Pyroptosis Pathway in Dry Eye Disease. [Abstract]

2021 Jul 5:14:2955-2962. PMID: 34262321
J Integr Med

Morin inhibits ubiquitination degradation of BCL-2 associated agonist of cell death and synergizes with BCL-2 inhibitor in gastric cancer cells. [Abstract]

2025 Apr 22:S2095-4964(25)00050-0. PMID: 40319008
Sci Rep

Cysteine-reactive mitigators of small vessel disease-related NOTCH3 mutants. [Abstract]

2026 Mar 20;16(1):14300. PMID: 41862552
Oncol Rep

HOTTIP suppresses ferroptosis via mediating DGCR8/miR‑214‑3p/GPX4 regulatory axis in osteosarcoma. [Abstract]

2025 Aug;54(2):94. PMID: 40539448
Sci Rep

Caerin 1.1 and 1.9 peptides induce acute caspase 3/GSDME-mediated pyroptosis in epithelial cancer cells. [Abstract]

2025 Apr 18;15(1):13377. PMID: 40251208
Sci Rep

Salvianolic acid A inhibits ferroptosis and protects against intracerebral hemorrhage. [Abstract]

2024 May 30;14(1):12427. PMID: 38816543
J Biol Chem

SLC25A3 negatively regulates NLRP3 inflammasome activation by restricting the function of NLRP3. [Abstract]

2024 May;300(5):107233. PMID: 38552738
Microbiol Spectr

CSFV restricts necroptosis to sustain infection by inducing autophagy/mitophagy-targeted degradation of RIPK3. [Abstract]

2024 Jan 11;12(1):e0275823. PMID: 38100396
Cell Signal

HDAC inhibitor enhances ferroptosis susceptibility of AML cells by stimulating iron metabolism. [Abstract]

2025 Jan 3:111583. PMID: 39756501
Mol Cell Biochem

A new gold(I) phosphine complex induces apoptosis in prostate cancer cells by increasing reactive oxygen species. [Abstract]

2025 Apr;480(4):2265-2276. PMID: 38782835
Biochim Biophys Acta Mol Cell Res

Modified 5-aminolevulinic acid photodynamic therapy induces cutaneous squamous cell carcinoma cell pyroptosis via the JNK signaling pathway. [Abstract]

2024 Jan;1871(1):119603. PMID: 37805058
Heliyon

Shenqi Sanjie Granules induce Hmox1-mediated ferroptosis to inhibit colorectal cancer. [Abstract]

2024 Sep 17;10(18):e38021. PMID: 39347400
Heliyon

VDAC1, as a downstream molecule of MLKL, participates in OGD/R-induced necroptosis by inducing mitochondrial damage. [Abstract]

2023 Dec 11;10(1):e23426. PMID: 38173512
J Cell Sci

AMBRA1 promotes dsRNA- and virus-induced apoptosis through interacting with and stabilizing MAVS. [Abstract]

2022 Jan 1;135(1):jcs258910. PMID: 34859815
Mol Med Rep

Oxalate‑induced renal pyroptotic injury and crystal formation mediated by NLRP3‑GSDMD signaling in vitro and in vivo. [Abstract]

2023 Nov;28(5):209. PMID: 37732544
Front Physiol

Mechanisms of Pancreatic Injury Induced by Basic Amino Acids Differ Between L-Arginine, L-Ornithine, and L-Histidine. [Abstract]

2019 Jan 15;9:1922. PMID: 30697165
Stem Cells Int

Shikonin Induces Glioma Necroptosis, Stemness Decline, and Impedes (Immuno)Proteasome Activity. [Abstract]

2024 Mar 14:2024:1348269. PMID: 39619148
J Cancer

SREBP1-SCD1 enhanced MUFAs Biosynthesis drives Nutrient Deprived Pancreatic cancer cell Ferroptosis Resistance. [Abstract]

2025 Sep 8;16(13):3960-3971. PMID: 41049011
J Pharm Pharmacol

Puerarin alleviates diabetic nephropathy by inhibiting Caspase-1-mediated pyroptosis. [Abstract]

2024 Mar 4;76(3):213-223. PMID: 38215026
Cardiovasc Drugs Ther

ALKBH5 Regulates Inflammation and Pyroptosis of Coronary Heart Disease by Targeting SPEN in a YTHDF1-Mediated Manner. [Abstract]

2025 Jul 26. PMID: 40715613
Cancer Med

Dihydroartemisinin Sensitizes Lung Cancer Cells to Cisplatin Treatment by Upregulating ZIP14 Expression and Inducing Ferroptosis. [Abstract]

2024 Oct;13(19):e70271. PMID: 39394878
Transbound Emerg Dis

Activation of ZBP1/RIPK3/MLKL-Dependent Necroptosis by Pseudorabies Virus Restricts Viral Infection in BV2 Microglia Cells. [Abstract]

2025 Oct 7:2025:8510846. PMID: 41098523
Mol Immunol

Coxsackievirus-A10 induced RIPK3-driven necroptosis to promote the formation of inflammatory response and enhance virus production via being recognized by TLR3. [Abstract]

2025 Jan 30:178:107-116. PMID: 39889589
Arch Biochem Biophys

Molecular mechanism by which RRM2-inhibitor (cholagogue osalmid) plus bafilomycin A1 cause autophagic cell death in multiple myeloma. [Abstract]

2023 Oct 1:747:109771. PMID: 37776936
Mol Immunol

Synergism of TNF-α and IFN-β triggers human airway epithelial cells death by apoptosis and pyroptosis. [Abstract]

2023 Jan:153:160-169. PMID: 36508750
Mol Immunol

Alteration of intestinal microecology by oral antibiotics promotes oral squamous cell carcinoma development. [Abstract]

2022 Sep:149:94-106. PMID: 35803000
Arch Biochem Biophys

FTY720 induces neutrophil extracellular traps via a NADPH oxidase-independent pathway. [Abstract]

2021 Oct 30:711:109015. PMID: 34437865
Am J Cancer Res

Necroptosis pathway blockage attenuates PFKFB3 inhibitor-induced cell viability loss and genome instability in colorectal cancer cells. [Abstract]

2021 May 15;11(5):2062-2080. PMID: 34094669
Cell Biochem Funct

A MARCKS Effector Domain-Derived Cytotoxic Peptide Induces Acute Tumor Cell Death. [Abstract]

2025 Nov;43(11):e70139. PMID: 41189474
J Integr Neurosci

Glucocorticoid Alleviates Stress-induced Hypothalamic Nerve Injury by Inhibiting the GSDMD-dependent Pyroptosis Pathway. [Abstract]

2025 Aug 21;24(8):39532. PMID: 40919628
Toxicon

Ursolic acid enhances radiosensitivity in esophageal squamous cell carcinoma by modulating p53/SLC7A11/GPX4 pathway-mediated ferroptosis. [Abstract]

2025 Jan 7:108233. PMID: 39788329
J Gene Med

NLRC4-mediated pyroptosis was involved in coagulation disorders of acute pancreatitis. [Abstract]

2024 Apr;26(4):e3683. PMID: 38571451
Clin Med Insights Oncol

MiR-339-5p Inhibits Ferroptosis by Promoting Autophagic Degradation of FTH1 Through Targeting ATG7 in Liver Cancer Cells. [Abstract]

2024 Apr 15:18:11795549241244783. PMID: 38628842
Transl Cancer Res

TAF1 inhibitor Bay-299 induces cell death in acute myeloid leukemia. [Abstract]

2021 Dec;10(12):5307-5318. PMID: 35116379
Hematology

Shikonin promotes ferroptosis though NSUN2-mediated m5C methylation modification of TFRC in acute myelocytic leukemia. [Abstract]

2025 Dec;30(1):2495221. PMID: 40270446
Res Sq

2026 May 18.
Res Sq

2026 Mar 11.
Res Sq

2026 Jan 22.
Npj Viruses

The soluble G protein of respiratory syncytial virus promotes viral dissemination via TLR2-mediated NLRP3 priming and pyroptosis. [Abstract]

2026 Jan 27;4(1):6. PMID: 41593203
bioRxiv

2024 September 26.
bioRxiv

RIPK1 is essential for Herpes Simplex Virus-triggered ZBP1-dependent necroptosis in human cells. [Abstract]

2024 Sep 19:2024.09.17.613393. PMID: 39345610
Res Sq

2024 May 13.
Research Square Preprint

2023 Oct 13.
Research Square Preprint

2023 Sep 15.
Research Square Preprint

2023 Jun 28.
Research Square Print

2023 Mar 16.
SSRN

26 Oct 2022.
Pharmacological Research-Modern Chinese Medicine

29 August 2022, 100157.
Oxid Med Cell Longev

Rosin Derivative IDOAMP Inhibits Prostate Cancer Growth via Activating RIPK1/RIPK3/MLKL Signaling Pathway. [Abstract]

2022 Aug 4:2022:9325973. PMID: 35965682
Oxid Med Cell Longev

Effect and Mechanism of LRP6 on Cardiac Myocyte Ferroptosis in Myocardial Infarction. [Abstract]

2021 Oct 19:2021:8963987. PMID: 34712388
Research Square Preprint

2021 May.
Research Square Preprint

2021 Jan.
bioRxiv

2020 Dec 14.

Solvent & Solubility

In Vitro:

DMSO : ≥ 28 mg/mL (60.68 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1670 mL

10.8349 mL

21.6699 mL

5 mM

0.4334 mL

2.1670 mL

4.3340 mL

10 mM

0.2167 mL

1.0835 mL

2.1670 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (5.42 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (5.42 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: 2.5 mg/mL (5.42 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 10 mg/mL (21.67 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 20% SBE-β-CD in Saline

Solubility: 6.67 mg/mL (14.45 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (290 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Sun L, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148(1-2):213-227. [Content Brief]

[2]. Wu YL, et al. Gasdermin D Inhibitor Necrosulfonamide Alleviates Lipopolysaccharide/D-galactosamine-induced Acute Liver Failure in Mice. J Clin Transl Hepatol. 2022 Dec 28;10(6):1148-1154. [Content Brief]

[3]. Kim DY, Leem YH, Kim HS. MLKL Inhibitor Reduces Oxidative Stress, Inflammation, and Dopaminergic Neuronal Cell Death in MPTP-Induced Parkinson's Disease Mouse Model. Biomol Ther (Seoul). 2025 May 1;33(3):429-437. [Content Brief]

[4]. Yang W, et al. Necrosulfonamide ameliorates intestinal inflammation via inhibiting GSDMD-medicated pyroptosis and MLKL-mediated necroptosis. Biochem Pharmacol. 2022 Dec;206:115338. [Content Brief]

[5]. Zhou XY, et al. The brain protection of MLKL inhibitor necrosulfonamide against focal ischemia/reperfusion injury associating with blocking the nucleus and nuclear envelope translocation of MLKL and RIP3K. Front Pharmacol. 2023 Oct 24;14:1157054. [Content Brief]

[6]. Zhang J, Wei K. Necrosulfonamide reverses pyroptosis-induced inhibition of proliferation and differentiation of osteoblasts through the NLRP3/caspase-1/GSDMD pathway. Exp Cell Res. 2021 Aug 15;405(2):112648. [Content Brief]

[7]. Liu Y, et al. Necrosulfonamide promotes hair growth and ameliorates DHT-induced hair growth inhibition. J Dermatol Sci. 2024 Aug;115(2):64-74. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1670 mL	10.8349 mL	21.6699 mL	54.1747 mL
	5 mM	0.4334 mL	2.1670 mL	4.3340 mL	10.8349 mL
	10 mM	0.2167 mL	1.0835 mL	2.1670 mL	5.4175 mL
	15 mM	0.1445 mL	0.7223 mL	1.4447 mL	3.6116 mL
	20 mM	0.1083 mL	0.5417 mL	1.0835 mL	2.7087 mL
	25 mM	0.0867 mL	0.4334 mL	0.8668 mL	2.1670 mL
	30 mM	0.0722 mL	0.3612 mL	0.7223 mL	1.8058 mL
	40 mM	0.0542 mL	0.2709 mL	0.5417 mL	1.3544 mL
	50 mM	0.0433 mL	0.2167 mL	0.4334 mL	1.0835 mL
	60 mM	0.0361 mL	0.1806 mL	0.3612 mL	0.9029 mL

Necrosulfonamide

140 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Necrosulfonamide

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Peptidomimetic Library

Anti-Aging Compound Library

Covalent Screening Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Pyroptosis Compound Library

Neuroprotective Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Protease Inhibitor Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cysteine Targeted Covalent Library

Mitochondrial Toxicity Compound Library

Autoimmune Disease Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Inflammasomes related Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Cell Death Inhibitor Library Mini

Anti-Aging Compound Library Mini

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Pattern Recognition Receptors Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Necrosulfonamide

All Caspase Isoforms

All NOD-like Receptor (NLR) Isoforms

All TNF Receptor Isoforms

All Interleukin Related Isoforms

All NO Synthase Isoforms

All Heme Oxygenase (HO) Isoforms

Biological Activity

Chemical Information

Publications (140)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Necrosulfonamide Related Classifications

Cat. No.: HY-100573